Literature DB >> 10437819

Adrenal suppression secondary to inhaled fluticasone propionate.

A V Taylor1, N Laoprasert, D Zimmerman, M I Sachs.   

Abstract

BACKGROUND: Inhaled glucocorticoids are the medical treatment of choice in many of patients with asthma. Fluticasone propionate is an inhaled glucocorticoid with little systemic bioavailability via the oral route and infrequent association with systemic adverse effects at the recommended dosage.
OBJECTIVE: To report a case of adrenal suppression and exogenous glucocorticoid excess from inhaled fluticasone propionate.
METHODS: A 9-year-old girl with a previous history of episodic asthma was placed on 550 microg of fluticasone propionate daily for severe labile asthma diagnosed by history and methacholine challenge. The patient returned 6 months later with complaints of increased appetite, nausea, and feeling "hot and flushed." On physical exam she had stigmata of Cushing's syndrome. The patient subsequently developed orthostatic hypotension and moderate dehydration following a viral illness. After a long taper of fluticasone propionate the patient' s adrenal function returned to normal and she had no acute or chronic exacerbations of her asthma.
RESULTS: Her 8 AM cortisol was undetectable with an ACTH of 21 pg/mL. The serum prolactin, TSH, free thyroxine, insulin-like growth factor I, and renin activity were all normal. An MRI study of her head was also normal. Repeat methacholine challenges while receiving a much smaller dose fluticasone propionate showed a significant decrease in airway reactivity.
CONCLUSION: Adrenal suppression can occur from inhaled fluticasone propionate at a dosage less than has been previously reported.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10437819     DOI: 10.1016/S1081-1206(10)63515-6

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  7 in total

1.  Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate.

Authors:  A J Drake; R J Howells; J P H Shield; A Prendiville; P S Ward; E C Crowne
Journal:  BMJ       Date:  2002-05-04

Review 2.  Antiasthmatic drug delivery in children.

Authors:  Elizabeth Biggart; Andrew Bush
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 4.  Safety of the newer inhaled corticosteroids in childhood asthma.

Authors:  Tabitha L Randell; Kim C Donaghue; Geoffrey R Ambler; Christopher T Cowell; Dominic A Fitzgerald; Peter P van Asperen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Systematic review of the dose-response relation of inhaled fluticasone propionate.

Authors:  M Masoli; M Weatherall; S Holt; R Beasley
Journal:  Arch Dis Child       Date:  2004-10       Impact factor: 3.791

6.  Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy.

Authors:  Alexandra Ahmet; Harold Kim; Sheldon Spier
Journal:  Allergy Asthma Clin Immunol       Date:  2011-08-25       Impact factor: 3.406

7.  Inhaled corticosteroids for cystic fibrosis.

Authors:  Ian M Balfour-Lynn; Karen Welch; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.